A study of exon-skipping drug GSK2402968 in nonambulatory subjects with DMD has opened at Nationwide Children's Hospital in Ohio
posted on June 18, 2010 - 11:58am
Update (Nov. 5, 2012): Results announced in November 2012 showed the drug, now called drisapersen, reached blood levels approximately proportional to the injected dose at two of the three dosage levels tested and was not associated with serious adverse events. See Drisapersen Appears Safe in Non-Walking Boys With DMD.
A multinational pharmaceutical company has committed to developing Prosensa's exon-skipping compound for DMD
posted on October 13, 2009 - 12:50pm
On Oct. 13, 2009, the multinational pharmaceutical company GlaxoSmithKline announced it will develop and commercialize the experimental “exon-skipping” compound PRO051 for Duchenne muscular dystrophy (DMD).
The commitment of a major pharmaceutical company to development of a drug for DMD is very good news for families with this disease.